[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"anxiety-disorders\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:anxiety-disorders":28},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,103,0,25,[9,49,78,107,151,179,215,239,264,300,328,357,381,403,432,470,492,514,544,574,597,622,648,668,692],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":30,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100059514","phase-2-study-of-neuro-cognitive-correlates-of-pediatric-anxiety-disorders-100059514",false,"NCT00018057","Study of Neuro-Cognitive Correlates of Pediatric Anxiety Disorders","* INCLUSION CRITERIA:\n\nALL JUVENILE SUBJECTS\n\n* Age: 8-17 (subjects who consent as 17-year-olds but turn 18 during the course of the study will be eligible to complete all procedures completed by other subjects who consent as 17-year-olds but do not turn 18).\n* Consent: can give consent\u002Fassent (Parents will provide consent; minors will provide assent)\n* IQ: all subjects will have IQ\\>70 (Assessment relies on either a WASI or assessment by trained clinical staff during the subject s screening visit. Completion of required activities during the screening visit requires an IQ above 70.)\n* Language: all subjects will speak English (Tasks in this protocol have not been validated in languages other than English)\n\nALL ADULT SUBJECTS\n\n* Age: 18-65\n* Consent: can give consent\n* IQ: all subjects will have IQ\\>70 (Assessment relies on either a WASI or assessment by trained clinical staff during the subject s screening visit. Completion of required activities during the screening visit requires an IQ above 70.)\n* Language: all subjects will speak English (Tasks in this protocol have not been validated in languages other than English)\n\nALL SUBJECTS WITH AN ANXIETY DISORDER\n\n* Diagnosis: Current Diagnosis of OCD, Social Phobia, Separation Anxiety, Generalized Anxiety Disorder, or Panic Disorder (Based on K-SADS (juveniles) or SCID (adults))\n* Symptom Severity: Clinically significant, ongoing anxiety symptoms (This will be documented by clinician review with patients and their families during at least two visits with families.)\n* Clinical Impairment: Clinically significant, ongoing distress or impairment from anxiety (This will be documented by clinician review with patients and their families during at least two visits with families.)\n\nALL PREVIOUSLY ENROLLED ADOLESCENT PATIENTS, CHILD AND ADULT HEALTHY VOLUNTEERS, AND ALL HEALTHY VOLUNTEERS TURNED PATIENTS\n\n* Diagnosis: Current Diagnosis of OCD, Social Phobia, Separation Anxiety, Generalized Anxiety Disorder, or Panic Disorder; No current diagnosis (Based on K-SADS (juveniles) or SCID (adults))\n* Clinical Impairment (as applicable): Clinically significant, ongoing symptoms (This will be documented by clinician review with patients and their families during at least two visits with families.)\n* Symptom Severity (as applicable): Clinically significant, ongoing symptoms (This will be documented by clinician review with patients and their families during at least two visits with families.)\n\nEXCLUSION CRITERIA:\n\nALL SUBJECTS\n\n* Any serious medical condition or condition that interferes with fMRI or M\u002FEEG scanning, and for patients electing medication, any condition that increases risk of SSRI treatment. (All patients will complete a medical history. Healthy volunteer participants will be medication- free and have no current serious medical conditions, based on a review of their medical history. Subjects only will be excluded from the MRI portions of the study based on this exclusion criterion.)\n* Pregnancy (Subjects only will be excluded from the MRI portions of the study based on this exclusion criterion.)\n* Current use of any psychoactive substance; current suicidal ideation as indicated by the presence of intent for engaging in suicidal behaviors; current diagnosis of attention deficit hyperactivity disorder (ADHD) of sufficient severity to require pharmacotherapy. (These factors could complicate treatment with an SSRI. No subject on medication will be accepted into the trial. Subjects will not be taken off of medications to enter the trial.)\n* Current diagnoses, major depressive disorder (MDD), post-traumatic distress disorder, conduct disorder. (These factors may be affected by SSRI treatment, influencing ability to detect effects on anxiety\u002Fsymptoms of depression. Of note, subjects who present with a diagnosis of MDD will not be eligible for inclusion at the outset of the study. However, youth with anxiety disorders frequently develop MDD when followed over time. Subjects will be allowed to remain in the study if they develop these diagnoses after enrollment.)\n* Past or current history of mania, psychosis, or severe pervasive developmental disorder. (These factors may be affected by SSRI treatment, influencing ability to detect effects on anxiety\u002Fsymptoms of depression. Of note, subjects who present with a diagnosis of MDD will not be eligible for inclusion at the outset of the study. However, youth with anxiety disorders frequently develop MDD when followed over time. Subjects will be allowed to remain in the study if they develop these diagnoses after enrollment.)\n* Recent use of an SSRI with failure to respond or tolerate SSRI treatment at an adequate dose and duration. (This is designed to exclude subjects who have failed a trial of an SSRI for their current problem with anxiety. For previously enrolled participants, including patients and healthy volunteers, current use of an SSRI does not exclude participation from follow-up research tasks.)\n* History of any (excepting nicotine-related and cannabis-related) DSM5-defined moderate to severe substance use disorder (or DSM-IV-defined substance dependence).\n\nHEALTHY ADULT SUBJECTS\n\n-Any current psychiatric diagnosis (Assessment relies on SCID)",true,"ALL","8 Years","65 Years",{"count":21,"type":22},3500,"ESTIMATED","INTERVENTIONAL",[25],"PHASE2","Study Description:\n\nThis study examines relations between neurocognitive and clinical features of pediatric anxiety disorders. The study uses neuro-cognitive tasks, functional magnetic resonance imaging (fMRI), as well as magneto- and electro-encephalography (M\u002FEEG). Patients will be studied over one year, before and after receiving either one of two standard-of-care treatments: cognitive behavioral therapy (CBT) or fluoxetine, a serotonin reuptake inhibitor (SSRI). Healthy comparisons will be studied at comparable time points.\n\nPrimary Objectives:\n\nTo compare healthy youth and symptomatic, medication-free pediatric patients studied prior to receipt of treatment. The study seeks to detect relations between clinical features of anxiety disorders at baseline and a wide range of neurocognitive features associated with attention, memory, and response to motivational stimuli.\n\nSecondary Objectives:\n\n1. To document relations between baseline neurocognitive features and response to Cognitive Behavioral Therapy (CBT) or fluoxetine, as defined by the Pediatric Anxiety Rating Scale (PARS) and Clinical Global Improvement (CGI) Scale.\n2. To document relations between post-treatment changes in neurocognitive features and anxiety symptoms on the PARS following treatment with Cognitive Behavioral Therapy (CBT) or fluoxetine.\n3. To document relations among broad arrays of clinical, cognitive, and neural measures\n\nPrimary Endpoints:\n\nIndices of percent-signal change in hypothesized brain regions, comprising amygdala, striatum, and prefrontal cortex (PFC) for each fMRI and MEG paradigm.\n\nSecondary Endpoints:\n\n1. Treatment-response as defined by a continuous measure, the Pediatric Anxiety Rating Scale score (PARS), and a categorial measure, the Clinical Global Improvement (CGI) score.\n2. Levels of symptoms and behaviors evoked by tasks that engage attention, memory, and elicit responses to motivational stimuli.",[28,29],"Anxiety Disorders","Major Depressive Disorder",[31,32,33,34,35],"fMRI","Emotion","Normal Volunteers","Magnetic Resonance Imaging","CBT","RECRUITING","2026-08-14",{"date":39,"type":40},"2026-08-17","ACTUAL",{"date":42,"type":40},"2001-10-02",{"date":44,"type":22},"2029-01-01",{"name":46,"class":47},"National Institute of Mental Health (NIMH)","NIH",2,{"id":50,"slug":51,"hasResults":12,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":4,"eligibilityCriteria":55,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":56,"enrollmentInfo":57,"targetDuration":4,"studyType":23,"phases":59,"briefSummary":60,"conditions":61,"keywords":63,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":77},"100561883","phase-2-gaze-contingent-music-therapy-augmentation-of-cbt-for-pediatric-anxiety-100561883","NCT06595953","Gaze-Contingent Music Therapy Augmentation of CBT for Pediatric Anxiety","Phase II Efficacy Study of Gaze-Contingent Music Therapy Augmentation of CBT for Pediatric Anxiety","* INCLUSION CRITERIA:\n\nIn order to be eligible to participate in this study, an individual must meet all of the following criteria:\n\n1. Ability of subject and parent to understand the study and the willingness to assent\u002Fconsent into the study.\n2. Males and females; Age 8-17\n3. Clinician confirmed diagnosis of ongoing separation anxiety disorder, generalized anxiety disorder, or social anxiety disorder. A clinician will review a KSADS-PL DSM-5 (November 2016) (Kiddie Schedule for Affective Disorders and Schizophrenia for School Aged Children) interview, which will have occurred on Protocol 01-M-0192, to confirm diagnosis\n4. Willingness to adhere to 12 weekly in-person sessions of CBT\n5. Enrolled in Protocol 01-M-0192\n6. Subjects must speak, read and write English to be able to participate\n7. All subjects will have IQ\\>70 as assessed by a WASI or assessment by trained clinical staff which will have occurred under Protocol 01-M-0192\n\nEXCLUSION CRITERIA:\n\nAn individual who meets any of the following criteria will be excluded from participation in this study:\n\n1. Current use of any psychotropic medication\n2. Ongoing participation in another treatment or intervention study\n3. Ongoing mental health treatment outside of NIH\n4. Any mental health diagnosis aside from an anxiety disorder as determined by the Kiddie Schedule for Affective Disorders and Schizophrenia (K-SADS)\n5. Any serious medical conditions\n6. Restrictions that preclude in-person attendance of therapy","17 Years",{"count":58,"type":22},150,[25],"Background:\n\nAnxiety disorders are becoming more common among children and teenagers. Anxiety can lead to long-term physical and mental problems, such as depression. Treatments for anxiety disorders include medications as well as cognitive behavioral therapy (CBT); CBT is a form of talking therapy. Both approaches work in only about 50 percent of cases. A new approach, called gaze-contingent music reward therapy (GCMRT), may help.\n\nObjective:\n\nTo find out whether GCMRT combined with CBT is more effective than CBT alone.\n\nEligibility:\n\nChildren aged 8 to 17 years with separation anxiety disorder; generalized anxiety disorder; or social anxiety disorder. They must be enrolled in protocol 01-M-0192.\n\nDesign:\n\nParticipants will come to the clinic once a week for 4 weeks for CBT. Sometimes the participant will meet with the doctor alone; sometimes their parent may be present. They will do some computer-based tasks: They may be asked to push a button when a target appears; they may look at pictures of faces while the computer tracks their eye movements. Participants will take questionnaires each week. They will answer questions about their anxiety symptoms, feelings, and behavior.\n\nFor the next 8 weeks, participants will participate in both CBT and 1 of 2 types of GCMRT.\n\nGCMRT is a computer-based task. Participants will look at pictures with many faces in them; while they do this, pleasant music will play and stop playing over a 12-minute period.\n\nParticipants will have a final visit in week 13. They will take questionnaires. They will do final research tasks. Each visit lasts about 2 hours.",[62,28],"Psychiatric Disorders",[64,65,66,67,68],"Cognitive-behavioral therapy","Attention","Anxiety","Children","Adolescents","2026-08-12",{"date":71,"type":40},"2026-08-13",{"date":73,"type":40},"2024-12-04",{"date":75,"type":22},"2029-10-01",{"name":46,"class":47},1,{"id":79,"slug":80,"hasResults":12,"nctId":81,"briefTitle":82,"officialTitle":83,"acronym":4,"eligibilityCriteria":84,"healthyVolunteers":16,"sex":17,"minAge":85,"maxAge":86,"enrollmentInfo":87,"targetDuration":4,"studyType":89,"phases":4,"briefSummary":90,"conditions":91,"keywords":96,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":101,"lastUpdatePostDateStruct":102,"startDateStruct":104,"completionDateStruct":4,"leadSponsor":106,"locationsCount":77},"100059955","evaluation-of-patients-with-mood-and-anxiety-disorders-and-healthy-volunteers-100059955","NCT00024635","Evaluation of Patients With Mood and Anxiety Disorders and Healthy Volunteers","The Evaluation of Patients With Mood and Anxiety Disorders and Healthy Volunteers","* INCLUSION CRITERIA:\n* Subjects ages 3 to 99 may enroll in the protocol.\n* Subjects must be competent to comprehend the purpose of the screening process and to provide written informed consent and be willing to participate in NIMH IRB approved research protocols. Minors will be asked to assent and their parents will sign the consent form.\n\nEXCLUSION CRITERIA:\n\n-Current alcohol or substance use or dependence (excluding nicotine) within the past 3 months of sufficient magnitude to require independent, concurrent treatment intervention (e.g. Antabuse or opiate treatment, but not including self-help groups).","3 Years","99 Years",{"count":88,"type":22},16000,"OBSERVATIONAL","The purpose of this protocol is to allow for the careful screening of patients and healthy volunteers for participation in research protocols in the Experimental Therapeutics and Pathophysiology Lab (ETPB) at the National Institute of Mental Health (NIMH) and for the collection of natural history data. In addition the protocol will allow clinicians to gain more experience in the use of a variety of polysomnographic and high-density EEG recordings. Subjects in this protocol will undergo an evaluation which may include: a psychiatric interview; a diagnostic interview; rating scales; a medical history; a physical exam; brain magnetic resonance imaging (MRI); electroencephalography (EEG); electrocardiography (EKG), magnetoencephalography (MEG); blood, saliva and urine laboratory evaluation; and a request for medical records. Subjects may also be asked to complete questionnaires about attitudes towards research and motivation for research participation. The data collected may also be linked with data from other mood and anxiety disorder protocols (e.g., brain imaging, DNA, psychophysiology tests, treatment studies, etc) for the purposes of better understanding the diagnosis, pathophysiology, and treatment response of patients with mood disorders. Parents of minors will be interviewed. Upon conclusion of the screening process, subjects will either be offered participation in a research protocol and will sign the appropriate informed consent, or will be considered not appropriate for participation in research and will be referred back into the community. The current protocol thus serves as an entry point for individuals with mood or anxiety disorders or healthy volunteers to enter NIMH IRB approved ETPB protocols.",[92,28,93,94,95],"Mood Disorders","Healthy Volunteers","Bipolar Disorder","Depression",[97,66,98,99,100],"Screening","Mood","Diagnostic Testing","Natural History","2026-08-08",{"date":103,"type":40},"2026-08-11",{"date":105,"type":40},"2001-02-02",{"name":46,"class":47},{"id":108,"slug":109,"hasResults":12,"nctId":110,"briefTitle":111,"officialTitle":112,"acronym":4,"eligibilityCriteria":113,"healthyVolunteers":12,"sex":17,"minAge":114,"maxAge":115,"enrollmentInfo":116,"targetDuration":4,"studyType":23,"phases":118,"briefSummary":120,"conditions":121,"keywords":130,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":141,"lastUpdatePostDateStruct":142,"startDateStruct":144,"completionDateStruct":146,"leadSponsor":148,"locationsCount":77},"100606821","creating-health-course-study-for-people-with-rheumatological-conditions-and-mood-disorders-100606821","NCT07180537","Creating Health Course Study for People With Rheumatological Conditions and Mood Disorders","Transforming Health Habits: Evaluating an Online Wellness Program for Individuals With Rheumatological Conditions and Mood Disorders","Inclusion criteria:\n\n1. A diagnosis of one of the following: Rheumatoid Arthritis (RA), Sjogren's Syndrome, Systemic lupus erythematosus (SLE), Mixed connective tissue disease (MCTD), or Psoriatic Arthritis (PsA), as documented by their treating specialist or primary care provider, as reported by the participant.\n2. Must be age 18 and older, at time of consent.\n3. Must be fluent in both speaking and reading English.\n\n   \\*Study participant must be able to read and comprehend informed consent document and speak with study staff about study document content. Study staff will use discretion in determining whether the study participant can clearly communicate with staff and comprehend the study material during the consent call or prior to the call.\n4. Must have access to high-speed internet with devices capable of audio\u002Fvideo streaming.\n5. Must be willing to participate in an online health course designed to improve dietary intake and self-care routines to help improve cellular function and health, and complete online surveys over the course of a 6-month period.\n6. Individuals must pass the Short Portable Mental Status Questionnaire with scores for normal mental functioning (up to 2 errors). Cognitive impairment as measured by the SPMS Questionnaire could interfere with the completion of the online course.\n\nSCORING\\* 0-2 errors: normal mental functioning 3-4 errors: mild cognitive impairment 5-7 errors: moderate cognitive impairment 8-10 errors: severe cognitive impairment\n\n\\*Allow one more error for a subject with only a grade school education. Allow one less error for a subject with education beyond high school.\n\nSource: Pfeiffer, E. (1975). A short portable mental status questionnaire for the assessment of organic brain deficit in elderly patients. Journal of American Geriatrics Society. 23, 433-41.\n\nExclusion criteria:\n\n1. Inability to provide informed consent, including participation in a consent call conducted via Zoom with the study team during business hours (8:00 a.m. to 5:00 p.m. Central Time (Chicago)).\n2. Participation in another research study investigating an intervention (treatments, medications, diet, or exercise). Participation in observation-only studies are not excluded.\n3. Currently following a modified Paleolithic, low-fat nutrient-dense vegetarian, or Mediterranean diet with 75% OR greater reported compliance.\n4. Any diagnosis or condition that is contraindicated from starting a gentle exercise program (ex. poorly controlled diseases of the heart, kidney, or liver in the prior 12 months, or severe psychiatric disease, e.g., schizophrenia, making adherence to study procedures difficult.","18 Years","100 Years",{"count":117,"type":22},400,[119],"NA","The goal of this project is to critically evaluate the effectiveness of an online health program designed to improve diet and self-care in patients with rheumatological conditions, including rheumatoid arthritis (RA), Sjogren's syndrome (SS), systemic lupus erythematosus (SLE), mixed connective tissue disease (MCTD), psoriatic arthritis (PsA), anxiety disorders, depressive disorders and moderate depression.\n\nAdditionally, investigators will assess the program's effectiveness, as well as the challenges and facilitators involved in using an online wellness program to reduce fatigue and enhance the quality of life in patients suffering from these conditions.",[122,123,124,125,126,28,127,128,129],"Rheumatoid Arthritis","Sjogren's Syndrome","Systemic Lupus Erythematosus","Mixed Connective Tissue Disease","Psoriatic Arthritis","Depressive Disorders","Moderate Depression","Moderate Anxiety",[131,132,133,134,135,136,137,138,139,140],"diet","self-care","internet course","anxiety","depression","Sjogren's","rheumatoid arthritis","lupus","fatigue","arthritis","2026-08-06",{"date":143,"type":40},"2026-08-10",{"date":145,"type":40},"2025-12-01",{"date":147,"type":22},"2027-12-31",{"name":149,"class":150},"Terry L. Wahls","OTHER",{"id":152,"slug":153,"hasResults":12,"nctId":154,"briefTitle":155,"officialTitle":155,"acronym":156,"eligibilityCriteria":157,"healthyVolunteers":12,"sex":17,"minAge":158,"maxAge":56,"enrollmentInfo":159,"targetDuration":4,"studyType":23,"phases":161,"briefSummary":162,"conditions":163,"keywords":166,"overallStatus":170,"whyStopped":4,"lastUpdateSubmitDate":171,"lastUpdatePostDateStruct":172,"startDateStruct":173,"completionDateStruct":175,"leadSponsor":177,"locationsCount":77},"100651053","feasibility-acceptability-and-preliminary-effectiveness-of-cognitive-behavioral-therapy-for-depression-in-autistic-youth-in-clinical-settings-100651053","NCT07755137","Feasibility, Acceptability, and Preliminary Effectiveness of Cognitive Behavioral Therapy for Depression in Autistic Youth in Clinical Settings","CBT-DAY","Inclusion Criteria:\n\nAutistic youth:\n\n* Age 11 to 17 years\n* Prior clinical diagnosis of autism (per record review)\n* At least a fifth grade reading level\n* An ability to engage in sessions verbally (i.e., full length sentences)\n* Elevated symptoms of depression at baseline (RCADS)\n* Depression is a current clinical concern and participant is appropriate for intervention (per investigator determination)\n* At least one parent\u002Fcaregiver willing and able to participate\n* Eligible to receive services at CHLA\n* If taking psychotropic medication, regimen must be stable for at least 8 weeks prior to baseline\n\nParents\u002FCaregivers:\n\n* Age 18 years or older\n* Parent or legal guardian of participating youth\n* Able to provide informed consent\n* Comfortable reading, writing, or speaking English or Spanish\n* Willing to participate in study procedures\n\nExclusion Criteria:\n\nAutistic youth:\n\n* Lifetime diagnosis of bipolar disorder, psychotic disorder, or intellectual disability\n* Severe suicidal or homicidal ideation or self-injury requiring immediate higher-level care\n* Currently receiving psychotherapy for depression\n* Changes in psychotropic medication regimen during study participation (participants may be withdrawn)\n* A reading level below fifth-grade\n* An inability to engage in sessions verbally (i.e., nonverbal, minimally verbal)\n\nParents\u002FCaregivers:\n\n* Not the parent or legal guardian of the participating youth\n* Unable to provide informed consent\n* Not comfortable reading, writing, or speaking English or Spanish\n* Unwilling to participate in study procedures","11 Years",{"count":160,"type":22},140,[119],"The goal of this clinical trial is to learn if Cognitive Behavioral Therapy for Depression in Autistic Youth (CBT-DAY) can improve depressive symptoms and related mechanisms in autistic youth aged 11-17 years with depression receiving care in outpatient clinical settings.\n\nThe main questions it aims to answer are:\n\n* Does CBT-DAY lead to greater reductions in depressive symptom severity compared to treatment-as-usual (TAU)?\n* Does CBT-DAY improve key mechanisms (emotional reactivity, self-esteem, and autism self-knowledge) associated with depression outcomes?\n\nResearchers will compare CBT-DAY versus treatment-as-usual (TAU) to see if CBT-DAY results in greater improvements in depressive symptoms and related outcomes.\n\nParticipants will:\n\n* Complete baseline, mid-treatment, post-treatment, and 3-month follow-up assessments (surveys and interviews)\n* Be randomly assigned to receive either 12 weeks of CBT-DAY or treatment-as-usual\n* Participate in therapy sessions during the 12-week intervention period\n* Complete follow-up assessments three months after treatment to evaluate longer-term outcomes",[164,165,28],"Autism Spectrum Disorder","Depressive Disorder",[135,167,168,134,169],"autism","youth","cognitive behavioral therapy","NOT_YET_RECRUITING","2026-08-05",{"date":143,"type":40},{"date":174,"type":22},"2026-12-01",{"date":176,"type":22},"2029-12-01",{"name":178,"class":150},"Children's Hospital Los Angeles",{"id":180,"slug":181,"hasResults":12,"nctId":182,"briefTitle":183,"officialTitle":184,"acronym":185,"eligibilityCriteria":186,"healthyVolunteers":12,"sex":17,"minAge":114,"maxAge":187,"enrollmentInfo":188,"targetDuration":4,"studyType":23,"phases":190,"briefSummary":191,"conditions":192,"keywords":197,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":171,"lastUpdatePostDateStruct":207,"startDateStruct":209,"completionDateStruct":211,"leadSponsor":213,"locationsCount":77},"100650815","efficacy-of-expectancy-focused-exposure-therapy-for-anxiety-disorders-100650815","NCT07753330","Efficacy of Expectancy Focused Exposure Therapy for Anxiety Disorders","Efficacy of Expectancy Focused Exposure Therapy in Reducing Fear and Preventing the Return of Anxiety Over Time: A Longitudinal Randomized Clinical Trial","EFE-AD","Population Description The study sample will consist of adult participants from the general population seeking psychological treatment for anxiety-related problems. Participants will be recruited through multiple sources, including university mental health services, student wellbeing units, community mental health centers, social media advertisements, and other public outreach channels. Recruitment will be intentionally broad to maximize accessibility and ecological validity.\n\nScreening and Selection Procedures Eligibility will be determined through a multi-stage screening process. Initial Screening: DSM-5 Cross-Cutting Measures, Levels 1 and 2 Participants responding to recruitment will first complete the DSM-5 Level 1 Cross-Cutting Symptom Measure (APA, 2013; Spanish version APA, 2014). This self-report instrument includes 23 items assessing 13 domains of psychopathology over the past 14 days using a 5-point Likert scale. It has shown good reliability and clinical utility in prior studies (APA, 2014; Bravo et al., 2018).\n\nParticipants who meet threshold criteria for anxiety-related symptoms on the Level 1 measure will then complete the corresponding DSM-5 Level 2 anxiety measures to further characterize symptom severity.\n\nDisorder-Specific Symptom Assessment, Level 3 Participants who meet screening criteria on Levels 1 and 2 will complete disorder-specific symptom scales according to the anxiety disorder suspected or reported, including measures for social anxiety disorder, specific phobia, generalized anxiety disorder, and panic disorder with or without agoraphobia.\n\nDiagnostic Assessment Participants who remain eligible after the screening and disorder-specific symptom assessment will undergo a structured clinical interview using the Anxiety and Related Disorders Interview Schedule for DSM-5 (ADIS-5). The ADIS-5 will be used to establish the principal anxiety disorder diagnosis and to assess exclusion criteria, including psychotic disorder, bipolar disorder, high suicide risk, and severe or uncontrolled substance use disorder.\n\nInclusion Criteria:\n\nParticipants must meet all of the following criteria:\n\n* Age between 18 and 70 years.\n* Seeking treatment for anxiety-related difficulties.\n* Meet DSM-5 diagnostic criteria for a principal anxiety disorder, including:\n\nsocial anxiety disorder, specific phobia, generalized anxiety disorder, panic disorder with or without agoraphobia.\n\n* Diagnosis will be established using the ADIS-5 structured clinical interview.\n* For participants with generalized anxiety disorder, treatment will focus on the principal anxiety problem identified during assessment.\n* Present clinically significant anxiety symptoms associated with the principal diagnosis.\n* If currently taking anxiolytic medication, the dosage must have remained stable for at least three months before the start of treatment and should be maintained during the treatment phase whenever possible.\n* Willingness and ability to participate in weekly psychotherapy sessions and complete all study assessments.\n* Provide informed consent.\n\nExclusion Criteria:\n\nParticipants will be excluded if any of the following conditions are present:\n\n* Current psychotic disorder.\n* Current manic or hypomanic episode, consistent with bipolar disorder.\n* High suicide risk requiring immediate clinical intervention.\n* Severe or uncontrolled substance use disorder.\n* Concurrent participation in psychological treatment specifically targeting the anxiety disorder during the study period.\n* Medical conditions that contraindicate exposure procedures (e.g., severe cardiovascular conditions).\n* Cognitive impairment or insufficient language proficiency that would interfere with participation in psychotherapy or completion of assessments.","70 Years",{"count":189,"type":22},203,[119],"This clinical trial evaluates whether an optimized exposure-based treatment improves long-term outcomes for adults with anxiety disorders. Specifically, it examines whether Expectancy Focused Exposure (EFE), based on the inhibitory learning model, is more effective than Anxiety Focused Exposure (AFE) in reducing anxiety symptoms and preventing the return of fear over time. The study includes adults aged 18 years and older diagnosed with an anxiety disorder, including social anxiety disorder, specific phobia, generalized anxiety disorder, and panic disorder with or without agoraphobia. Anxiety disorders are highly prevalent and can significantly interfere with daily functioning, work performance, and interpersonal relationships. Exposure therapy is a central component of cognitive behavioral treatment for anxiety disorders. Traditional exposure approaches often focus on reducing anxiety during exposure sessions, but many individuals experience a return of fear after treatment. New theoretical models suggest that exposure may be more effective when designed to violate threat expectations and strengthen inhibitory learning. Participants will be recruited in sequential cohorts and randomly assigned to immediate treatment or a brief waitlist before treatment begins. Those assigned to the waitlist will start treatment at the next study step. When treatment begins, participants will receive either EFE or AFE. Both treatments consist of approximately 10 weekly individual psychotherapy sessions delivered by trained therapists. Participants will complete clinical assessments before treatment, during treatment, immediately after treatment, and at 6, 12, and 18 months after treatment completion. In AFE, exposure exercises are organized along an anxiety hierarchy and focus on reducing anxiety responses through repeated confrontation with feared stimuli. In EFE, exposure focuses on identifying and testing threat expectations, and exercises are designed to maximize expectancy violation and strengthen inhibitory learning. Potential risks include temporary emotional discomfort during exposure exercises. All sessions will be conducted by trained clinicians who monitor participant safety throughout the study. The results may help improve exposure-based treatments for anxiety disorders by identifying strategies that enhance long-term outcomes and reduce relapse.",[28,193,194,195,196],"Panic Disorder","Social Anxiety Disorder (SAD)","Generalised Anxiety Disorder","Specific Phobia",[198,199,200,201,202,203,28,204,205,206],"Exposure Therapy","Randomized Controlled Trial","Expectancy Violation","Optimized Exposure","Inhibitory Retrieval Model","Extinction Learning","Associative Map","Fear Extinction","Relapse Prevention",{"date":208,"type":40},"2026-08-07",{"date":210,"type":40},"2026-07-01",{"date":212,"type":22},"2029-03-31",{"name":214,"class":150},"University of Chile",{"id":216,"slug":217,"hasResults":12,"nctId":218,"briefTitle":219,"officialTitle":219,"acronym":220,"eligibilityCriteria":221,"healthyVolunteers":12,"sex":17,"minAge":114,"maxAge":86,"enrollmentInfo":222,"targetDuration":4,"studyType":23,"phases":224,"briefSummary":225,"conditions":226,"keywords":227,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":171,"lastUpdatePostDateStruct":232,"startDateStruct":233,"completionDateStruct":235,"leadSponsor":237,"locationsCount":77},"100370696","understanding-the-person-exploring-change-across-psychotherapies-100370696","NCT04106713","Understanding the Person, Exploring Change Across Psychotherapies","Xchange","Inclusion Criteria:\n\n1. For patients:\n\n   1. 18-99 years old;\n   2. have current or past symptoms of anxiety and\u002For depression;\n   3. able to communicate and read in English;\n   4. able to provide informed consent.\n   5. Waitlist arm:\n\n      \\- Referred for psychotherapy but given a waiting time of 8 weeks or more to the first visit or not assigned to therapy at IMH.\n   6. Treatment as usual:\n\n      \\- Not assigned to any psychotherapeutic interventions.\n   7. iCBT: - Referred for iCBT;\n\n      \\- Identified as a 'P2' patient\u002Fappropriate for iCBT by triage.\n   8. Group therapy:\n\n      \\- Referred for group therapy;\n\n      \\- Identified as a 'P2' patient\u002Fappropriate for group therapy by triage.\n   9. Individual psychotherapy:\n\n      * Referred for individual therapy;\n      * Patient and therapist committed to frequent therapy (ideally fortnightly).\n2. For therapists:\n\n   1. Therapists who will see OR have been assigned to clients in the waitlist arm, iCBT, group therapy (e.g. PsychUp), and individual psychotherapy group.\n\nExclusion Criteria:\n\n1\\. For patients:\n\n1. current active suicidal intention or plan;\n2. cognitively-impaired\u002Fare unable to consent\u002Flack capacity to consent.",{"count":223,"type":22},250,[119],"Identifying predictors and understanding mechanisms of change will inform referral to psychotherapy, triage and right-siting by helping clinicians to understand how their patients are likely to benefit from clinical interventions. This study will be the first of its kind conducted in an Asian hospital setting to identify the predictors of response to individual, group and internet-delivered CBT for the treatment of depressed and anxious patients in the Institute of Mental Health (IMH), Singapore. With increasing challenges with hospital workload, there is an increasing emphasis on group and online interventions. Understanding of the factors that may predict outcome from these therapies can improve right-siting by identifying who will get better without therapy or who may not benefit from a given form of therapy and guide personalisation of care. An important biological predictor of outcome is likely to be genetic risk as it has been demonstrated that patients with greater melancholia and a family history may not be sufficiently treated with brief courses of therapy. Identifying psychological factors underlying psychological distress and determining the extent to which these factors are addressed by these interventions will help to improve and individualise existing psychotherapy and motivate new psychotherapeutic interventions.",[95,28],[228,229,230,231],"Psychotherapy","Cognitive behavioural therapy","Group psychotherapy","Internet-based psychotherapy",{"date":141,"type":40},{"date":234,"type":40},"2019-10-04",{"date":236,"type":22},"2026-09-30",{"name":238,"class":150},"Institute of Mental Health, Singapore",{"id":240,"slug":241,"hasResults":12,"nctId":242,"briefTitle":243,"officialTitle":243,"acronym":4,"eligibilityCriteria":244,"healthyVolunteers":12,"sex":17,"minAge":114,"maxAge":245,"enrollmentInfo":246,"targetDuration":4,"studyType":23,"phases":248,"briefSummary":249,"conditions":250,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":255,"lastUpdatePostDateStruct":256,"startDateStruct":258,"completionDateStruct":260,"leadSponsor":262,"locationsCount":77},"100490845","mindful-self-compassion-for-anxiety-disorders-and-depression-100490845","NCT05671419","Mindful Self-Compassion for Anxiety Disorders and Depression","Inclusion Criteria:\n\n* Must have a primary anxiety disorder (social anxiety disorder, generalized anxiety disorder, panic disorder, or agoraphobia) or major depressive disorder, current\n* Must score low on self-compassion, as measured by the self-compassion scale\n* Must understand study procedure and willing to participate in all testing visits, and treatment as assigned\n* must be able to give informed consent to the study procedures\n\nExclusion Criteria:\n\n* Comorbid psychiatric disorder other than anxiety or depression, such as psychotic disorder, obsessive compulsive disorder, eating disorders (i.e., anorexia and bulimia), bipolar disorder; developmental or organic mental disorders; and current (past 6 months) substance use disorders and current post-traumatic stress disorder as assessed by clinician at screening visit\n* A serious medical condition that may result in surgery or hospitalization.\n* A history of head trauma causing prolonged loss of consciousness, or ongoing cognitive impairment\n* Inability to understand study procedures or informed consent process, or significant personality dysfunction likely to interfere with study participation (assessed during the clinical interview).\n* Subjects who will be non-compliant with the study procedures. This may include planned travel out of town.\n* Subjects taking some psychiatric medication such as barbiturates or antipsychotics. Sleep medications and some anti-depressants will be allowed, if the subject has been taken at stable dose 8 weeks prior to baseline and the patient plans to continue at the same dose through the trial.\n* Concurrent psychotherapy initiated within 1 month of screen interview, or ongoing psychotherapy of any duration directed specifically toward the treatment of anxiety (such as Cognitive Behavioral Therapy).\n* Individuals who have completed a course of MSC or an equivalent meditation training in the last year.\n* Individuals reporting significant active suicidal ideation or suicidal behaviors within the past year.\n* Individuals with a medical condition (i.e., epilepsy) that may be exacerbated by study treatment, as determined by a study physician or nurse practitioner based on history, physical, and\u002For labs.\n* Adults unable to consent\n* Pregnant women\n* Prisoners","75 Years",{"count":247,"type":22},40,[119],"The study will compare 8-week Mindful Self-Compassion training, compared to a control group that does not receive the intervention, on anxiety and depression symptom severity in patients with diagnosed anxiety disorders (generalized anxiety disorder, social anxiety disorder, and panic disorder) or major depressive disorder.",[28,251,252,253,193,254,29],"Generalized Anxiety Disorder","Social Anxiety Disorder","Social Phobia","Agoraphobia","2026-07-27",{"date":257,"type":40},"2026-07-29",{"date":259,"type":40},"2022-01-16",{"date":261,"type":22},"2026-07",{"name":263,"class":150},"Georgetown University",{"id":265,"slug":266,"hasResults":12,"nctId":267,"briefTitle":268,"officialTitle":269,"acronym":270,"eligibilityCriteria":271,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":56,"enrollmentInfo":272,"targetDuration":4,"studyType":23,"phases":274,"briefSummary":275,"conditions":276,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":291,"lastUpdatePostDateStruct":292,"startDateStruct":293,"completionDateStruct":295,"leadSponsor":297,"locationsCount":299},"100522340","phase-2-sertraline-vs-placebo-in-the-treatment-of-anxiety-in-children-and-adolescents-with-neurodevelopmental-disorders-100522340","NCT06081348","Sertraline vs. Placebo in the Treatment of Anxiety in Children and AdoLescents With NeurodevelopMental Disorders","A Randomized Placebo-Controlled Trial of Sertraline vs. Placebo in the Treatment of Anxiety in Children and AdoLescents With NeurodevelopMental Disorders","CALM","Inclusion Criteria:\n\n1. Outpatients 8-17 years of age, inclusive\n2. Females of child bearing potential who are sexually active and agree to use medically acceptable birth control throughout the study and at least one week post last dose of study drug.\n3. Meet Diagnostic and Statistical Manual of Mental Disorders - DSM-5 criteria for ASD, ADHD, Tic Disorders, or genetic diagnosis of Fragile X, tuberous sclerosis or 22q11 deletions.\n4. Meet DSM-5 criteria for one of the following anxiety disorders: Separation Anxiety Disorder, Social Anxiety Disorder, Agoraphobia, Generalized Anxiety Disorder, or Unspecified Anxiety Disorder, based on expert clinical interview, supported by the Kiddie Schedule for Affective Disorders and Schizophrenia (KSADS; Kaufman et al., 2016). Other specified anxiety disorder is included to account for youth with impairing anxiety symptoms who may not meet criteria for one of the other anxiety disorders.\n5. Have a Clinician's Global Impression-Severity for anxiety (CGI-S; Guy, 1976)) score ≥ 4 (moderately ill) (inter-rater reliability will be done prior to initiation of enrollment, using videotapes of interviews and vignettes)\n6. If already receiving interventions, must meet the following criteria:\n\n   1. If receiving concomitant medications affecting behaviour, must be on a stable dose during the month prior to screening and will not electively modify ongoing medications for study duration\n   2. If already receiving stable non-pharmacological behavioural interventions, have stable participation during 3 months prior to screening, and will not electively modify ongoing interventions\n7. Ability to complete assessments in English\n\nExclusion Criteria:\n\n1. Receiving other SSRIs within four weeks of randomization (6 weeks for fluoxetine)\n2. Previous treatment with sertraline, at an adequate dose (at least 100mg for 6 weeks, or lower dose and duration if not well-tolerated), associated with no response or significant-to-the-participant side effects.\n3. Received more than 2 previous appropriate trials of SSRIs with no adequate response\n4. Pregnant females or sexually active females on inadequate contraception\n5. Serious medical condition that, based on Investigator judgment, might interfere with the conduct of the study, confound interpretation of the study results, or endanger participant. In addition diabetic patients on medications for glycemic control will be excluded as sertraline may interfere with glycemic control.\n6. Hypersensitivity to sertraline or any components of its formulation\n7. On Monoamine Oxidase Inhibitors or pimozide (as per product monograph)\n8. On concomitant medications known to significantly increase QT interval where this would result in unacceptable risk per Investigator judgment.\n9. Known congenital QT prolongation\n10. HIV, hepatitis B or C, hemophilia, abnormal blood pressure, substance abuse, immunity disorder, major depressive episode or psychosis (as required by Health Canada)\n11. Unable to tolerate venipuncture\n12. Unable to swallow capsules\n13. Enrolled in another intervention study",{"count":273,"type":22},130,[25],"There are currently no approved medications for the treatment of anxiety in children and youth with neurodevelopmental disorders (NDDs), both common and rare. Sertraline, a selective serotonin reuptake inhibitor, has extensive evidence to support its use in children's and youth with anxiety but not within NDDs. More research is needed to confirm whether or not sertraline could help improve anxiety in children and youth with common and rare neurodevelopmental conditions. This is a pilot study, in which we plan to estimate the effect size of reduction in anxiety of sertraline vs. placebo. across rare and common neurodevelopmental disorders, and determine the best measure(s) to be used as a primary transdiagnostic outcome measure of anxiety, as well as diagnosis specific measures in future, larger-scale clinical trials of anxiety in NDDs.",[277,278,164,279,280,281,282,283,284,285,286,287,288,289,290,66,28],"Neurodevelopmental Disorders","Autism","Fragile X Syndrome","Tuberous Sclerosis","22Q11 Deletion Syndrome","22Q11 Deletion","ADHD","Tic Disorders","Tourette Syndrome","Tourette Syndrome in Children","Tourette Syndrome in Adolescence","ADHD - Combined Type","ADHD Predominantly Inattentive Type","ADHD, Predominantly Hyperactive - Impulsive","2026-07-24",{"date":255,"type":40},{"date":294,"type":40},"2024-09-16",{"date":296,"type":22},"2027-09",{"name":298,"class":150},"Holland Bloorview Kids Rehabilitation Hospital",7,{"id":301,"slug":302,"hasResults":12,"nctId":303,"briefTitle":304,"officialTitle":304,"acronym":4,"eligibilityCriteria":305,"healthyVolunteers":12,"sex":17,"minAge":114,"maxAge":115,"enrollmentInfo":306,"targetDuration":4,"studyType":23,"phases":308,"briefSummary":309,"conditions":310,"keywords":312,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":318,"lastUpdatePostDateStruct":319,"startDateStruct":321,"completionDateStruct":323,"leadSponsor":325,"locationsCount":327},"100585148","enhancing-engagement-by-integrating-goals-and-concerns-that-matter-to-patients-100585148","NCT06898593","Enhancing Engagement by Integrating Goals and Concerns That Matter to Patients","Inclusion Criteria:\n\n* Patients enrolled in the Collaborative Care Model (CoCM) at Dartmouth Health\n\nExclusion Criteria:\n\n* Patients not enrolled in the Collaborative Care Model (CoCM) at Dartmouth Health",{"count":307,"type":22},2448,[119],"The goal of this clinical trial is to learn if adding patients' goals and concerns to measurement-based collaborative care can tailor care and provide a more holistic view of treatment, thereby improving engagement in care among adult patients receiving collaborative care. The main questions it aims to answer are:\n\n* Does using a clinical decision support system (which includes an enhanced pre-visit questionnaire and patient-level dashboard) improve patient engagement in the collaborative care model?\n* Does using a clinical decision support system improve patient and clinician satisfaction with care?\n\nResearchers will compare the enhanced collaborative care with traditional collaborative care.\n\nPatient participants will complete pre-visit questionnaires before their collaborative care appointments. Responses will be viewed by the clinician and\u002For patient in a visual dashboard inside the electronic health record.",[28,311],"Depression Disorders",[313,314,315,316,95,66,317],"Collaborative Care Model","pre-visit questionnaire","dashboard","clinical decision support system","integrated behavioral health and primary care","2026-07-21",{"date":320,"type":40},"2026-07-22",{"date":322,"type":40},"2025-04-02",{"date":324,"type":22},"2028-07-31",{"name":326,"class":150},"Dartmouth-Hitchcock Medical Center",6,{"id":329,"slug":330,"hasResults":12,"nctId":331,"briefTitle":332,"officialTitle":333,"acronym":334,"eligibilityCriteria":335,"healthyVolunteers":12,"sex":17,"minAge":114,"maxAge":4,"enrollmentInfo":336,"targetDuration":4,"studyType":89,"phases":4,"briefSummary":338,"conditions":339,"keywords":343,"overallStatus":170,"whyStopped":4,"lastUpdateSubmitDate":349,"lastUpdatePostDateStruct":350,"startDateStruct":351,"completionDateStruct":353,"leadSponsor":355,"locationsCount":4},"100648341","prognosis-of-epilepsy-with-post-traumatic-stress-disorder-and-surgery-100648341","NCT07718542","Prognosis of Epilepsy With Post-traumatic Stress Disorder and Surgery","Surgical Prognosis for Drug-resistant Focal Epilepsy Associated With Post-traumatic Stress Disorder (PTSD): a Multidimensional Assessment of the Success of Resective Surgery.","PEPSY","Inclusion Criteria:\n\n* Adults aged 18 years or older\n* Individuals informed about the study who do not object to participation\n* Individuals with drug-resistant focal epilepsy (failure of at least two appropriately selected and adequately administered anti-seizure medications)\n* Eligible for resective epilepsy surgery and awaiting surgery\n* Covered by the French health insurance system\n\nExclusion Criteria:\n\n* Concurrent participation in another research study that precludes enrollment\n* Individuals unable to provide informed participation according to French regulations, covered by Articles L1121-5 to L1121-8 of the French Public Health Code\n* Individuals who do not understand French\n* Individuals with generalized epilepsy\n* Individuals whose epilepsy is controlled with anti-seizure medication\n* Contraindication to resective epilepsy surgery",{"count":337,"type":22},42,"Why is this study being conducted? For people with drug-resistant focal epilepsy, surgery, to remove the part of the brain where seizures start, is currently the most effective treatment. In many people, especially those with temporal lobe epilepsy, surgery can stop seizures completely and improve quality of life. However, doctors usually predict the chances of surgical success using brain scans and other neurological tests, while the possible influence of psychological and social factors remains less well understood.\n\nMental health is an important part of overall health. People living with epilepsy are more likely than the general population to experience anxiety, depression, and post-traumatic stress disorder (PTSD). PTSD can develop after experiencing traumatic events and may affect emotional well-being, daily activities, relationships, and physical health.\n\nSome studies suggest that PTSD may affect brain networks involved in epilepsy. This raises an important question: could PTSD influence the success of epilepsy surgery? We hypothesize that PTSD and other psychological or social factors may affect surgical outcomes and recovery after surgery. At present, there is limited evidence available to answer this question.\n\nWhat is the aim of the study? The main objective of this study is to determine whether PTSD affects the success of epilepsy surgery two years after the operation.\n\nThe study also aims to:\n\n* Describe the medical, psychological, and social characteristics of people undergoing epilepsy surgery and estimate how common traumatic experiences and PTSD are in this population;\n* Assess changes in PTSD symptoms, anxiety, depression, quality of life, social vulnerability, and patient satisfaction before and after surgery;\n* Identify biological, psychological, and social factors associated with successful surgical outcomes.\n\nRather than focusing only on seizure control, this study aims to improve understanding of the factors that contribute to recovery, quality of life, and long-term well-being after epilepsy surgery. The findings may help healthcare professionals provide more personalized support before and after surgery.\n\nWho can take part? Between September 2026 and September 2028, the study will recruit 42 adults with drug-resistant focal epilepsy who are being evaluated for resective epilepsy surgery at Timone University Hospital in Marseille, France.\n\nWhat does participation involve? Participants will join the study approximately three months before surgery and will be followed for two years after the operation.\n\nDuring routine pre-operative and post-operative follow-up visits, participants will complete validated self-report questionnaires about:\n\n* Traumatic experiences and PTSD symptoms;\n* Anxiety and depression;\n* Quality of life;\n* Social vulnerability;\n* Satisfaction with surgery. Participants whose questionnaire results suggest possible PTSD will be offered a routine psychiatric assessment to confirm the diagnosis. Based on these assessments, participants will be classified into one of two groups: people with PTSD and people without PTSD.\n\nThe study will also use clinical information routinely collected as part of epilepsy care, including brain imaging, electroencephalography (EEG), and neuropsychological assessments.\n\nWhat are the expected benefits of this research? This study may improve understanding of how psychological and social factors influence epilepsy surgery outcomes. The results may help healthcare professionals better identify patients who could benefit from additional support before and after surgery.\n\nIn the future, the findings could contribute to the development of more personalized care pathways, including advanced practice nursing follow-up, improved mental health screening, and targeted support to enhance seizure outcomes, quality of life, emotional well-being, and patient satisfaction after epilepsy surgery",[340,341,28,342],"Epilepsies, Focal","Drug Restistant Epilepsie","Post-traumatic Stress Disorder (PTSD)",[344,345,346,347,348],"Epilepsy surgery","Drug-resistant focal epilepsy","Post-traumatic stress disorder","Surgical outcomes","Advanced practice nursing","2026-07-17",{"date":320,"type":40},{"date":352,"type":22},"2026-09",{"date":354,"type":22},"2031-05",{"name":356,"class":150},"Assistance Publique Hopitaux De Marseille",{"id":358,"slug":359,"hasResults":12,"nctId":360,"briefTitle":361,"officialTitle":362,"acronym":4,"eligibilityCriteria":363,"healthyVolunteers":16,"sex":17,"minAge":114,"maxAge":19,"enrollmentInfo":364,"targetDuration":4,"studyType":89,"phases":4,"briefSummary":366,"conditions":367,"keywords":368,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":375,"lastUpdatePostDateStruct":376,"startDateStruct":378,"completionDateStruct":4,"leadSponsor":380,"locationsCount":77},"100087463","development-of-magnetic-resonance-imaging-techniques-for-studying-mood-and-anxiety-disorders-100087463","NCT00397111","Development of Magnetic Resonance Imaging Techniques for Studying Mood and Anxiety Disorders","Development of Functional and Structural Magnetic Resonance Imaging Techniques for the Study of Mood and Anxiety Disorders","* INCLUSION CRITERIA:\n\nHealthy Controls\n\n* Male and female subjects between 18 and 65 years of age\n* Subjects must be able to give written informed consent prior to participation in this study.\n* Subjects who do not currently meet and have never met criteria for any major psychiatric disorder, and who have no known first degree relatives with mood disorders.\n* For cognitive experiments utilizing language stimuli only native English speakers will be enrolled.\n\nMajor Depressive Disorder\n\n* Male and female subjects between 18 and 65 years of age.\n* Subjects have been found eligible for other ETPB research protocols according to 01-M-0254.\n* Subjects must fulfill DSM-IV or V criteria for Major Depression based on clinical assessment and confirmed by a structured diagnostic interview (SCID-P).\n* Subjects must be able to give written informed consent prior to participation in this study.\n* For cognitive experiments utilizing language stimuli, only native English speakers will be enrolled.\n\nEXCLUSION CRITERIA:\n\nHealthy Control\n\n* Subjects with major medical or neurological disorders expected to influence cerebral blood flow or morphology, or taking any medication that is likely to influence the imaging parameters-of-interest within 3 weeks of scanning.\n* Women who are pregnant are excluded from the study. Subjects will undergo pregnancy testing no more than 24 hours prior to MRI scanning.\n* Subjects with contraindication to MRI scanning such as aneurysm clips, implanted neural stimulator, implanted cardiac pacemaker or auto-defibrillator, cochlear implant, or ocular foreign body.\n* A history of drug or alcohol abuse within 1 year or a lifetime history of drug or alcohol dependence (DSM-IV) or alcohol use disorder (DSM-V equivalent).\n\nMajor Depressive Disorder\n\n* Presence of Axis 1 psychiatric diagnosis other than Major Depression or an Axis 2 disorder\n* Subjects with major medical or neurological disorders expected to influence cognitive function or are taking any drugs likely to affect mood or cognitive function within 1 week of study participation. Depressed subjects will not be tapered\u002Fwithdrawn from medications under this study.\n* A history of drug or alcohol abuse within 1 year or a lifetime history of drug or alcohol dependence (DSM-IV) or alcohol use disorder (DSM-V equivalent).\n* Subjects with major medical or neurological disorders expected to influence cerebral blood flow or morphology.\n* Women who are pregnant or breastfeeding will be excluded from MRI portions of the study. Subjects will undergo pregnancy testing no more than 24 hours prior to MRI scanning.\n* Subjects with contraindication to MRI scanning such as aneurysm clips, implanted neural stimulator, implanted cardiac pacemaker or auto-defibrillator, cochlear implant, or ocular foreign body.",{"count":365,"type":22},390,"This study is intended to help develop new MRI imaging techniques for studying mood and anxiety disorders. Researchers believe that depression and anxiety disorders may cause structural and functional changes in the brain. This study will optimize the way MRI scans are collected to look at brain structure and examine how the brain behaves while subjects perform particular tasks. Healthy volunteers and individuals with major depressive disorder may be eligible for this study.\n\nParticipants undergo magnetic resonance imaging (MRI) and neuropsychological testing. : Individuals will be asked to participate in an MRI study on one of several scanners. The scanner used will measure blood flow in the brain, concentrations of certain chemicals in the brain, or magnetic properties of the brain. The scan may involve They watching a screen presenting images or doing a task in which they respond to pictures or sounds. Participants may be asked to return for additional scans.\n\nThe study also involves neuropsychological tests, which assess cognitive performance. Often, people with mood disorders have subtle changes in performance on these tests that allow researchers to pinpoint where brain abnormalities occur. Before the tests can be used in patients, they must be validated by using healthy subjects. These tests are presented either orally, in written form, or on a computer.",[92,28],[369,370,31,371,372,100,373,374],"Morphometry","BOLD","Spectrometry","Relaxometry","Healthy Volunteer","HV","2026-07-15",{"date":377,"type":40},"2026-07-16",{"date":379,"type":40},"2006-12-06",{"name":46,"class":47},{"id":382,"slug":383,"hasResults":12,"nctId":384,"briefTitle":385,"officialTitle":386,"acronym":4,"eligibilityCriteria":387,"healthyVolunteers":12,"sex":17,"minAge":388,"maxAge":389,"enrollmentInfo":390,"targetDuration":4,"studyType":23,"phases":392,"briefSummary":393,"conditions":394,"keywords":4,"overallStatus":170,"whyStopped":4,"lastUpdateSubmitDate":395,"lastUpdatePostDateStruct":396,"startDateStruct":397,"completionDateStruct":399,"leadSponsor":401,"locationsCount":4},"100647309","myfilm-a-pilot-study-for-social-emotional-learning-in-clinical-youth-100647309","NCT07708168","MyFILM: A Pilot Study for Social-Emotional Learning in Clinical Youth","MyFILM: A Pilot Study for Social Emotional Learning in Clinical Youth","Inclusion Criteria:\n\n* Be between 9 and 12 years of age at enrollment\n* Be receiving outpatient care through Sunnybrook Health Sciences Centre\n* Demonstrate elevated risk (first-degree relative with a mental illness, experiencing a major life stressor as judged by the treating physician and investigator), subclinical symptoms (symptoms of a mood and\u002For anxiety disorder that do not meet the threshold of a clinical diagnosis), or diagnosed mood and\u002For anxiety-related concerns\n* Be able to participate in group-based discussions and activities in English\n* Have parent\u002Fguardian consent and participant assent\n\nExclusion Criteria:\n\n* Have active psychosis or mania\n* Have severe cognitive, developmental, and\u002For behavioural limitations preventing meaningful participation","9 Years","12 Years",{"count":391,"type":22},48,[119],"The objective of this pilot study is to evaluate the feasibility and acceptability of MyFILM as a weekly group intervention for children aged 9-12 in a clinical setting. We will also gather preliminary data to explore changes in clinical metrics following participation in MyFILM in preparation for a full-scale clinical trial.\n\nPrimary Objective (Feasibility): To determine whether a substantial proportion of participants complete the MyFILM intervention.\n\nPrimary Objective (Acceptability): To determine whether the MyFILM intervention is acceptable to 9-12-year-old participants in a clinical setting.\n\nSecondary Objective (Clinical Effectiveness): To determine whether participation in MyFILM show preliminary evidence of improvement in social-emotional skills, coping ability, and reduction in anxiety and depression symptoms.\n\nParticipants will:\n\nParticipate in 9 sessions of a structured group-based program.",[92,28],"2026-07-12",{"date":377,"type":40},{"date":398,"type":22},"2026-09-01",{"date":400,"type":22},"2028-03-31",{"name":402,"class":150},"Mark Sinyor",{"id":404,"slug":405,"hasResults":12,"nctId":406,"briefTitle":407,"officialTitle":408,"acronym":4,"eligibilityCriteria":409,"healthyVolunteers":12,"sex":17,"minAge":389,"maxAge":410,"enrollmentInfo":411,"targetDuration":4,"studyType":23,"phases":413,"briefSummary":414,"conditions":415,"keywords":417,"overallStatus":170,"whyStopped":4,"lastUpdateSubmitDate":423,"lastUpdatePostDateStruct":424,"startDateStruct":426,"completionDateStruct":427,"leadSponsor":429,"locationsCount":431},"100644110","digital-coach-to-support-exposure-therapy-homework-for-anxious-youth-100644110","NCT07666672","Digital Coach to Support Exposure Therapy Homework for Anxious Youth","Randomized Controlled Trial of the BraveBot Intervention as an Adjunctive Treatment for Young People With Anxiety and Related Disorders Receiving Outpatient, Exposure-Based Cognitive Behavioral Therapy","INCLUSION CRITERIA (youth participants):\n\n1. Has a clinical or subclinical anxiety or related disorder (e.g., panic disorder, social anxiety disorder, obsessive-compulsive disorder) for which exposure-based CBT is indicated.\n2. Between the ages of 12 and 22 years at the time of enrollment.\n3. Is either (a) currently receiving exposure-based CBT (or CBT in which exposure-based content is expected to be a core component) at a participating MGB outpatient program, or (b) on the waitlist for a participating program and expected to initiate exposure-based CBT in the near future.\n4. Sufficient ability to communicate in English (study materials, measures, and the BraveBot interface are currently English-only). For minors, at least one parent\u002Fguardian must be sufficiently proficient in English to understand the consent information.\n5. The youth and\u002For caregiver has access to a device that can receive SMS text reminders and open secure web links to complete exposure homework and brief post-exposure surveys.\n\nEXCLUSION CRITERIA (present at enrollment):\n\n1. Symptoms of suicidal or homicidal ideation, psychosis, or a non-anxiety-related primary mental health concern (i.e., where treatment for a disorder other than anxiety is indicated prior to exposure treatment, or independent exposure homework is not clinically appropriate as determined by the treating clinician). Examples include: current substance use or dependence requiring specialized or higher-level care that must be addressed before or instead of anxiety-focused exposure-based CBT; and current eating disorder severe enough to require intensive\u002Fspecialized treatment such that exposure-based CBT for anxiety\u002FOCD is not the appropriate primary focus.\n2. Youth is unable to complete homework independently.\n3. Any other condition or circumstance for which treatment for another primary psychiatric condition is clearly indicated prior to anxiety-focused exposure-based CBT, or for which out-of-session exposure homework is considered unsafe or inappropriate.\n\nThe investigators will also recruit up to 10 clinicians at participating programs who may use the BraveBot system with their patients (who have enrolled in the study independently) and complete brief baseline and end-of-study surveys.","22 Years",{"count":412,"type":22},50,[119],"This study is testing a digital tool called BraveBot for young people who are receiving cognitive behavioral therapy (CBT) for anxiety, OCD, or related problems. BraveBot is a computer program, not a person. It talks with youth through their phone or computer while they do \"face-your-fears\"-style exposure therapy homework that their therapist has assigned. Sometimes an exposure is done with BraveBot's real-time coaching, and sometimes on their own; after each exposure, youth answer a few short questions about how it went.\n\nRather than dividing participants into separate groups, the study randomizes each individual exposure homework assignment. Every time a young person opens an eligible exposure, the system makes a 1:1 random assignment deciding whether that exposure is completed with BraveBot's support or independently (self-guided).\n\nThe main goal is to learn whether using BraveBot helps youth understand their exposure assignments better, put in more effort, stick with exposures when they are hard, feel more capable, and find exposures more helpful in \"fighting back\" against anxiety. The study also examines whether BraveBot increases the likelihood that assigned exposures are completed, and explores effects on anxiety symptoms and how safe, easy to use, and useful BraveBot feels for youth, their therapists, and parents.\n\nBraveBot does not replace the therapist, diagnose, or design exposures; it only supports the homework the clinician has assigned, and is used under clinician oversight. A built-in safety system can detect possible risk-related language, pause the session, show crisis resources (such as 988), and notify the treating clinician. The study is conducted within routine outpatient psychology clinics at Mass General Brigham. Up to 40 youth ages 12-22 will take part.",[28,416],"OCD",[134,418,419,420,421,422],"exposure therapy","pediatric","large language model","conversational AI","randomized controlled trial","2026-06-18",{"date":425,"type":40},"2026-06-24",{"date":375,"type":22},{"date":428,"type":22},"2027-07-15",{"name":430,"class":150},"Massachusetts General Hospital",3,{"id":433,"slug":434,"hasResults":12,"nctId":435,"briefTitle":436,"officialTitle":436,"acronym":4,"eligibilityCriteria":437,"healthyVolunteers":16,"sex":17,"minAge":114,"maxAge":438,"enrollmentInfo":439,"targetDuration":4,"studyType":23,"phases":441,"briefSummary":442,"conditions":443,"keywords":446,"overallStatus":170,"whyStopped":4,"lastUpdateSubmitDate":423,"lastUpdatePostDateStruct":462,"startDateStruct":464,"completionDateStruct":466,"leadSponsor":468,"locationsCount":77},"100527171","whole-body-hyperthermia-for-mood-and-anxiety-disorders-100527171","NCT06144294","Whole-Body Hyperthermia for Mood and Anxiety Disorders","Inclusion Criteria\n\n* Group 2\n\n  * Arm 1: Healthy women or transgender men 18-50 years of age, ≤ 6 months postpartum\n  * Arm 2: Women and transgender men 18-50 years of age, ≤ 6 months postpartum, meeting criteria for a major depressive episode in the postpartum period on the MINI.\n  * Arm 3: Healthy adults of both sexes 18-50 years of age.\n  * Arm 4: Adults of both sexes 18-50 years of age meeting criteria for an episode of major depression or generalized anxiety disorder on the Mini International Neuropsychiatric Interview (MINI)\n* Group 2: Sub-study\n\n  * Subjects enrolled in Group 2 are eligible for an optional additional sub-study (Group 2: Sub-study); inclusion criteria are the same as for Group 2.\n\nExclusion criteria for all:\n\n* For logistics, we will exclude individuals with BMI \\>30 and waist size \\> 35, who may not fit comfortably in the sauna dome for all cohorts described above.\n* For contraindications to hyperthermia, we will exclude from all cohorts listed above, individuals with severe cardiovascular disease, including congestive heart failure, coronary artery disease, uncontrolled hypertension, and hypotension; pregnancy; active substance use disorders; recent major injuries or surgeries (\\\u003C1 week prior); impaired sweating (those with multiple sclerosis, diabetes mellitus with neuropathy, central nervous system disease, heat insensitivity); a history or family history of malignant hyperthermia, fever or active signs of infection; taking medications that may have interactions with hyperthermia (for example, barbiturates, diuretics, and beta blockers) and the use of an antipyretic or anihistamine medication in the 12 hours prior to the WBH intervention. Individuals with above mentioned conditions will be excluded since either WBH might deteriorate their conditions or it is unknown how their condition will be affected by WBH.\n* For contraindications to immune analyses, we will exclude individuals with conditions that might affect immune analyses, including individuals with known active autoimmune or endocrine disease and individuals with active infection at baseline.\n\nAdditional exclusion criteria by cohort or applicable study group:\n\n* Group 2\n\n  * Arm 1: For psychiatric contraindications, we will exclude individuals with a history of psychiatric disorders as assessed by MINI since the cohort will consist of mentally healthy individuals as a control group.\n  * Arm 2: For psychiatric contraindications, we will exclude individuals with bipolar disorder or other Axis I psychiatric disorders except depressive and anxiety disorders and individuals taking antidepressants who are unwilling to hold antidepressant dose steady from recruitment through study termination. In this cohort we exclude individuals with other psychiatric disorders except depressive and anxiety disorders to rule out the effect of other psychiatric diseases on the outcome.\n  * Arm 3: For psychiatric contraindications, we will exclude individuals with a history of psychiatric disorders as assessed by MINI since the cohort will consist of mentally healthy individuals as a control group.\n  * Arm 4: For psychiatric contraindications, we will exclude individuals with bipolar disorder or other Axis I psychiatric disorders except depressive and anxiety disorders and individuals taking antidepressants who are unwilling to hold antidepressant dose steady from recruitment through study termination. In this cohort we exclude individuals with other psychiatric disorders except depressive and anxiety disorders to rule out the effect of other psychiatric diseases on the outcome.\n* Group 2 and Group 2: Sub-study - All participants\n\n  * For contraindications to use of the e-Celsius capsule that will be used to measure core temperature, we will exclude individuals with pacemakers or any other electric medical implant, individuals with a current intestinal disorder that could lead to obstruction of the digestive tract including gastroparesis, individuals with history of diverticula, individuals with history of past surgical procedures in the gastrointestinal tract, individuals with a swallowing disorder and individuals with Crohn's disease.\n* Study Group 3 - All participants\n\n  * For contraindications to MRI, individuals with metal in the body will be excluded from participating in the MRI portion of the research since magnetic fields in MRI scanners can cause dangerous interactions in patients with metallic foreign bodies: projectile effect, twisting, burning, artifacts, and device malfunction (interference with a pacemaker).","50 Years",{"count":440,"type":22},240,[119],"This study aims to examine the scientific mechanisms of whole-body hyperthermia (WBH), a novel, rapidly acting, single session antidepressant and anxiolytic therapy. It also aims to determine its feasibility and acceptability in women with postpartum depression (PPD). The study will enroll four cohorts of participants: healthy postpartum controls; postpartum women with PPD; healthy adult controls; and adults with major depressive disorder or anxiety disorders in a longitudinal protocol.",[444,92,28,445],"Postpartum Depression","Postpartum Anxiety",[447,448,449,450,451,452,453,454,455,456,457,458,459,460,461,31],"postpartum depression","mood disorders","anxiety disorders","postpartum anxiety","whole-body hyperthermia","antidepressant therapy","anxiolytic therapy","postpartum feasibility and acceptability","psychoneuroimmunology","Broad-band neural suppression","EEG","Likert scale","inflammatory activity","pro-inflammatory cytokines","precision functional brain maps",{"date":463,"type":40},"2026-06-23",{"date":465,"type":22},"2028-06",{"date":467,"type":22},"2032-12",{"name":469,"class":150},"Weill Medical College of Cornell University",{"id":471,"slug":472,"hasResults":12,"nctId":473,"briefTitle":474,"officialTitle":475,"acronym":4,"eligibilityCriteria":476,"healthyVolunteers":12,"sex":17,"minAge":389,"maxAge":4,"enrollmentInfo":477,"targetDuration":4,"studyType":23,"phases":479,"briefSummary":480,"conditions":481,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":483,"lastUpdatePostDateStruct":484,"startDateStruct":486,"completionDateStruct":488,"leadSponsor":490,"locationsCount":77},"100642990","feasibility-study-of-up-a-ast-parent-group-for-adolescents-with-autism-and-co-occurring-anxietydepression-100642990","NCT07637799","Feasibility Study of UP-A-AST Parent Group for Adolescents With Autism and Co-occurring Anxiety\u002FDepression","Unified Protocol-Adolescent Autism Parent Group (UP-A-AST) for Adolescents With Autism Spectrum Disorder and Co-occurring Anxiety and\u002For Depressive Disorders: A Feasibility Study","Inclusion Criteria:\n\n* Adolescents aged 12-17 years\n* Clinical diagnosis of autism spectrum disorder (ASD) according to DSM-IV, DSM-5, or ICD-10\n* Current diagnosis of anxiety disorder and\u002For depressive disorder according to DSM-5\n* Ongoing contact with a Child and Adolescent Psychiatry (BUP) outpatient clinic\n* Stable psychopharmacological treatment at the time of inclusion (if applicable)\n* Parents has participated in a psychoeducational program on autism within child and adolescent psychiatric services, or is assessed by the clinician to have equivalent knowledge\n\nExclusion Criteria:\n\n* Presence of a severe psychiatric disorder, such as psychotic disorder, bipolar disorder, or severe eating disorder\n* High suicide risk or suicide attempt within the past 12 months\n* Severe self-injurious behavior\n* Intellectual disability according to DSM-5\n* The adolescent is primarily in need of basic interventions for autism spectrum disorder\n* Parents are unable to attend all group sessions and\u002For lack the ability to engage in assigned home practice\n* Need for an interpreter",{"count":478,"type":22},72,[119],"Autism spectrum disorder (ASD) is associated with high rates of psychiatric comorbidity, particularly anxiety and depressive disorders, which contribute to significant impairment for affected youth and their families. Although cognitive behavioral therapy (CBT) is recommended as a first-line treatment for anxiety and depression in children and adolescents, there is a lack of evidence-based interventions specifically adapted for youth with ASD and co-occurring emotional disorders.\n\nThe Unified Protocol for Transdiagnostic Treatment of Emotional Disorders in Children and Adolescents (UP-C\u002FUP-A) is a CBT-based intervention targeting shared mechanisms underlying anxiety and depression. A parent-mediated adaptation, the Unified Protocol-Adolescent Autism Parent Group (UP-A-AST), has been developed to address the specific needs of adolescents with ASD and co-occurring anxiety and\u002For depressive disorders. Preliminary quality improvement work has shown promising results.\n\nThis study aims to evaluate the feasibility, acceptability, and preliminary effects of the UP-A-AST Parent Group in a child and adolescent outpatient psychiatric setting. The study will include parents of adolescents aged 12-17 years with ASD and co-occurring anxiety and\u002For depressive disorders. Outcomes include changes in adolescents' psychiatric symptoms and functional impairment, as well as parents' perceived parenting competence. Additionally, parents' experiences of participating in the intervention will be explored.",[482,28,165],"Autistic Spectrum Disorder","2026-06-09",{"date":485,"type":40},"2026-06-10",{"date":487,"type":40},"2026-01-05",{"date":489,"type":22},"2027-03-30",{"name":491,"class":150},"Sahlgrenska University Hospital",{"id":493,"slug":494,"hasResults":12,"nctId":495,"briefTitle":496,"officialTitle":496,"acronym":4,"eligibilityCriteria":497,"healthyVolunteers":12,"sex":17,"minAge":498,"maxAge":499,"enrollmentInfo":500,"targetDuration":4,"studyType":23,"phases":502,"briefSummary":503,"conditions":504,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":483,"lastUpdatePostDateStruct":507,"startDateStruct":509,"completionDateStruct":511,"leadSponsor":513,"locationsCount":77},"100513239","development-of-a-transdiagnostic-intervention-for-adolescents-at-risk-for-serious-mental-illness-100513239","NCT05962879","Development of a Transdiagnostic Intervention for Adolescents at Risk for Serious Mental Illness","Inclusion Criteria:\n\n* Currently enrolled in 9th through 12th grade and between the ages of 14 and 19\n* Endorsed at least one psychotic experience\n* Provided contact information\n* Have a parent or legal guardian who is able and willing to provide written informed consent (if under the age of 18)\n* Have a parent or legal guardian who is able and willing to participate in a parent session\n* Competent and willing to provide written informed assent (if under the age of 18) or consent (if age 18 or older)\n* Able to communicate in English\n\nExclusion Criteria:\n\n* Currently prescribed psychotropic medication (not including medications for attention deficit\u002Fhyperactivity disorder), regardless of adherence\n* Currently obtaining psychotherapeutic intervention","14 Years","19 Years",{"count":501,"type":22},70,[119],"This research study aims to develop a brief group-based treatment called Resilience Training for Teens, then to test how well it protects high school students with mild symptoms of depression, anxiety, or having unusual feelings from developing mental illnesses.",[28,505,165,506],"Psychotic Disorders","Psychosocial Functioning",{"date":508,"type":40},"2026-06-11",{"date":510,"type":40},"2024-03-22",{"date":512,"type":22},"2027-05-31",{"name":430,"class":150},{"id":515,"slug":516,"hasResults":12,"nctId":517,"briefTitle":518,"officialTitle":518,"acronym":4,"eligibilityCriteria":519,"healthyVolunteers":12,"sex":17,"minAge":520,"maxAge":114,"enrollmentInfo":521,"targetDuration":4,"studyType":23,"phases":523,"briefSummary":524,"conditions":525,"keywords":531,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":536,"lastUpdatePostDateStruct":537,"startDateStruct":538,"completionDateStruct":540,"leadSponsor":542,"locationsCount":77},"100642279","experimental-evidence-of-the-impact-of-parental-income-on-child-mental-health-and-neuroimmune-function-100642279","NCT07641244","Experimental Evidence of the Impact of Parental Income on Child Mental Health and Neuroimmune Function","Inclusion Criteria:\n\n* Child of a participant enrolled in the Every Dollar Counts intervention. Youth were between ages 5 and 14 at the start of the intervention (followed up when ages 10 to 18)\n* Biological parent who lives with the child must be part of the original income study\n* For the in-person neuroimaging subsample: family must live within a 2-hour drive of downtown Chicago\n\nExclusion Criteria:\n\n* Youth not between ages 5 and 14 at the start of the intervention\n* Parent not enrolled in the Every Dollar Counts program","10 Years",{"count":522,"type":22},500,[119],"Growing up in a lower-income family robustly predicts worse mental health in adolescence and early adulthood. How does variability in family income \"get under the skin\" of the developing child and via what mechanisms does it increase risk for mental illness? Moreover, could supplements to family income at critical developmental periods help to prevent later youth mental illness? To address these questions, we leverage an innovative existing double blind randomized controlled trial of 3-years of substantial income supplements to parents.\n\nBy experimentally studying the impacts of these income supplements on families and subsequent youth development, we can examine causal pathways from family income to risk for mental illness via family stress and neuroimmune mechanisms in ways never done before. Moreover, by measuring the longer-term impact of 3 years of income supplements to parents on their child's neuroimmune signaling and risk for mental illness, we can examine the policy implications for child development of unconditional cash transfers to parents and identify how and for whom these supplements help. We will test these basic and translational questions in a sample of 1,200 youth with lower-income parents randomly assigned to receive either a substantial monthly income supplement or a minimal monthly supplement for 3 years, starting when youth were between age 5 - 14 years old. We will follow up with youth and their parent 1 - 2 and 3 - 4 years after the intervention and examine whether income supplements predict better youth mental health during adolescence, as well as whether factors like child age and neighborhood quality modulate intervention effects. Additionally, we explore family stress mechanisms through which the intervention may impact child mental health. Finally, we will measure peripheral inflammation (inflammatory biomarkers and classical monocytes) and use MRI to assess threat, reward, and regulatory neural activity and connectivity among 500 of these youth. Our central hypothesis is that income supplements will decrease family and youth stress and improve parenting, which will improve neuroimmune signaling and decrease risk for psychopathology. Moreover, these effects will remain years after termination of the transfers and be strongest among families who received the intervention earlier in the child's life. This research will provide timely, relevant public health knowledge that will help policy makers understand the longer-term brain, immune, and mental health impacts of cash transfers to parents, while also advancing the science of the sociocontextual and neuroimmune pathways through which variability in family income impacts risk for psychopathology.",[526,527,28,528,529,530],"Psychopathology","Child Mental Health","Mental Disorders","Inflamation","Poverty",[95,66,532,533,534,530,527,526,535],"Internalizing Disorders","Externalizing Disorders","Inflammation","Stress","2026-06-08",{"date":508,"type":40},{"date":539,"type":40},"2026-04-04",{"date":541,"type":22},"2029-08-31",{"name":543,"class":150},"Northwestern University",{"id":545,"slug":546,"hasResults":12,"nctId":547,"briefTitle":548,"officialTitle":549,"acronym":550,"eligibilityCriteria":551,"healthyVolunteers":16,"sex":17,"minAge":552,"maxAge":114,"enrollmentInfo":553,"targetDuration":4,"studyType":23,"phases":555,"briefSummary":556,"conditions":557,"keywords":559,"overallStatus":170,"whyStopped":4,"lastUpdateSubmitDate":567,"lastUpdatePostDateStruct":568,"startDateStruct":569,"completionDateStruct":571,"leadSponsor":572,"locationsCount":77},"100642699","study-on-mental-health-promoting-effects-of-natural-psychotherapy-for-adolescents-100642699","NCT07639476","Study on Mental Health Promoting Effects of Natural Psychotherapy for Adolescents","The Effect of Universal Intervention Based on Natural Psychotherapy: Evidence From Chinese Adolescents","NP-A-MHP","Inclusion Criteria:\n\n* Ages: 7 to 18 years.\n* Population: School-aged children and adolescents currently enrolled and attending primary or secondary school.\n* Capacity: Ability to comprehend the study procedures and provide assent (or consent, if applicable).\n\nExclusion Criteria:\n\n* School Attendance: Children not currently attending school or on long-term academic leave.\n* General Exclusion: Any condition that, in the opinion of the investigator or school physician, would interfere with the participant's ability to attend school or comply with study procedures.","7 Years",{"count":554,"type":22},3000,[119],"This randomized controlled trial aims to evaluate the efficacy of a universal intervention based on Natural Psychotherapy in reducing anxiety and depressive symptoms among primary and middle school students. To evaluate both the clinical outcomes and the potential underlying mechanisms of change, data will be collected at four distinct time points: baseline (pre-intervention), post-intervention, 3-month follow-up, and 6-month follow-up.",[28,165,558],"Mental Health",[560,95,561,562,563,564,565,566],"Mindfulness","Emotional Regulation","Cognitive Flexibility","Primary School Students","Middle School Students","Feasibility","Natural Psychotherapy","2026-06-06",{"date":485,"type":40},{"date":570,"type":22},"2026-09-15",{"date":147,"type":22},{"name":573,"class":150},"Beijing HuiLongGuan Hospital",{"id":575,"slug":576,"hasResults":12,"nctId":577,"briefTitle":578,"officialTitle":579,"acronym":580,"eligibilityCriteria":581,"healthyVolunteers":12,"sex":17,"minAge":114,"maxAge":115,"enrollmentInfo":582,"targetDuration":4,"studyType":23,"phases":583,"briefSummary":584,"conditions":585,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":588,"lastUpdatePostDateStruct":589,"startDateStruct":591,"completionDateStruct":593,"leadSponsor":595,"locationsCount":431},"100489874","rxwell-to-decrease-post-operative-opioid-use-in-total-knee-or-hip-arthroplasty-100489874","NCT05658796","RXWell to Decrease Post-Operative Opioid Use in Total Knee or Hip Arthroplasty","Telemedicine-delivered Digital Cognitive Behavioral Intervention to Decrease Post-operative Opioid Use Among Patients Undergoing Total Knee or Hip Arthroplasty","RxWell","Inclusion Criteria for the RXWell Study:\n\n* Adults \\>18 years\n* Scheduled for elective primary total knee arthroplasty (TKA) or hip replacement (THA) at the approved UPMC hospitals\n* Moderately high levels of mood disorder symptoms on validated PROMIS measures, defined as a T-score \\> or = to 60 on PROMIS Anxiety 4a short form and\u002For PROMIS Depression4a short form\n\nExclusion Criteria for the RXWell Study:\n\n* Patients undergoing non-elective surgery or secondary arthroplasty\n* Active delirium, neurocognitive impairment, or severe intellectual disability\n* No access to a smart device (phone or tablet)\n* Active alcoholism (defined as daily use of more than 1 liter of wine and \u002For 3 or more shots of hard liquor) or drug abuse (defined as daily use of illicit drugs)\n* Profound mood disorders requiring immediate intervention such as suicidal ideation, defined as a PROMIS Depression score of more than 70\n* A PROMIS Anxiety and\u002For Depression T-score \\>70, which corresponds to severe anxiety and depression.\n\n  * Patients needing immediate care will be referred to psychiatrists and primary team.",{"count":58,"type":22},[119],"It is envisioned that multipronged benefits from this pilot work for the UPMC ISD and its members. It is expected the RxWell platform to provide the following benefits: expansion of the use of RxWell to all UPMC ISD members providing peri-operative mood management with advantage of improved peri-operative outcomes, improving saving for the UPMC ISD by hastening the recovery and decreased resource utilization, and addition to the high-value care of UPMC with this holistic approach to patient perioperative care",[92,66,586,95,28,587],"Depressive Symptoms","Anxiety Depression","2026-06-01",{"date":590,"type":40},"2026-06-03",{"date":592,"type":40},"2023-01-27",{"date":594,"type":22},"2026-12-30",{"name":596,"class":150},"University of Pittsburgh",{"id":598,"slug":599,"hasResults":12,"nctId":600,"briefTitle":601,"officialTitle":602,"acronym":603,"eligibilityCriteria":604,"healthyVolunteers":12,"sex":17,"minAge":605,"maxAge":187,"enrollmentInfo":606,"targetDuration":4,"studyType":23,"phases":608,"briefSummary":609,"conditions":610,"keywords":611,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":613,"lastUpdatePostDateStruct":614,"startDateStruct":616,"completionDateStruct":618,"leadSponsor":619,"locationsCount":621},"100489695","clinical-study-evaluating-pharmacogenomics-informed-pharmacotherapy-versus-dosing-as-usual-in-psychiatric-disorders-100489695","NCT05656469","Clinical Study Evaluating Pharmacogenomics-informed Pharmacotherapy Versus Dosing as Usual in Psychiatric Disorders","A New Intervention for Implementation of Pharmacogenetics in Psychiatry","PSY-PGx","Inclusion Criteria:\n\n1. Suffer from a depressive episode (major depressive disorder and bipolar disorder (currently depressive episode)) (as assessed by the MINI International Neuropsychiatric Interview (M.I.N.I.) in agreement with Diagnostic and Statistical Manual (DSM-5 criteria) of at least moderate severity (assessed using the Structured Interview Guide for the Hamilton Depression Scale (SIGH-D) with a score of 14 or higher) and\u002For suffer from an anxiety disorder (panic disorder, generalised anxiety disorder) (as assessed by the M.I.N.I. in agreement with DSM-5 criteria) of at least moderate severity (assessed using the Structured Interview Guide for the Hamilton Anxiety Scale (SIGH- A) with a score of 18 or higher) and\u002For suffer from a psychotic disorder (schizophrenia and schizoaffective disorder) (as assessed by the M.I.N.I. in agreement with DSM-5 criteria) of at least moderate severity (assessed using the Positive and Negative Symptom Scale (PANSS) with a score of 75 or higher).\n2. Have had an inadequate response to at least 1 psychotropic treatment during their life-time. Inadequate response is defined as insufficient efficacy of a psychotropic treatment when dosed high enough and maintained long enough, or discontinuation of a psychotropic treatment due to AEs or intolerability.\n3. Are about to switch (or have switched within the last 2 weeks prior to first contact with an investigator) to sertraline or escitalopram (for patients with mood or anxiety disorders), or to aripiprazole or risperidone (for patients with psychotic disorders) due to an inadequate response to or intolerance of the current\u002F previous medication.\n4. Currently receiving inpatient or outpatient psychiatric treatment.\n5. Be able to understand the requirements of the study and provide written informed consent to participate in this study; a signed and dated informed consent form (ICF) will be obtained from each patient before participation in the study.\n6. To give written consent to the use and disclosure of clinical data from their medical records for the purpose of this study.\n7. Age between ≥16 and \\\u003C70 years.\n8. Ownership of a mobile phone (Android or iOS operation system) for passive monitoring.\n\nExclusion Criteria:\n\n1. Patients with a history of prior pharmacogenomic testing\n2. Patients with no prior use of psychotropic medication (medication-naïve patients)\n3. Severe somatic comorbidities as reported in the subject's medical history or based on clinical chemistry\u002Felectrocardiography (ECG) results up to six months ago. If any of these comorbidities is detected on the basis of physical examination and\u002For clinical chemistry and\u002For ECG at the screening visit, participation is not possible.\n\n   * Liver disease defined as follows: Alanine-Aminotransferase (ALAT) \\>70u\u002FL\n   * Renal disease: Estimated glomerular filtration rate (eGFR) \\\u003C 60ml\u002Fmin\u002F1.73m2\n   * Diabetes: Blood glucose \\> 11.1 mmol\u002FL or twice a fasting glucose \\> 7.0 mmol\u002FL\n   * Cardiac disease: prolonged QT-interval.\n4. Alcohol and\u002For substance abuse and\u002For dependence (except nicotine)\n5. Polypharmacy defined as the routine use of five or more medications including over- the-counter, prescription and\u002For traditional and complementary medicines used by a patient (WHO 2019).\n6. Inability to use the mobile phone application\n7. Pregnant or breastfeeding women","16 Years",{"count":607,"type":22},2500,[119],"A 24-week, patient- and rater-blinded, two-arm, parallel-group controlled, and multi-centre randomized clinical trial (RCT) to establish the benefits of pharmacogenetics-informed pharmacotherapy versus dosing as usual (DAU) in psychiatric patients suffering from mood, anxiety, or psychotic disorders.",[92,28,505],[612],"Pharmacogenetics","2026-05-29",{"date":615,"type":40},"2026-06-02",{"date":617,"type":40},"2023-02-23",{"date":352,"type":22},{"name":620,"class":150},"Parnassia Groep",9,{"id":623,"slug":624,"hasResults":12,"nctId":625,"briefTitle":626,"officialTitle":627,"acronym":628,"eligibilityCriteria":629,"healthyVolunteers":12,"sex":17,"minAge":630,"maxAge":56,"enrollmentInfo":631,"targetDuration":4,"studyType":89,"phases":4,"briefSummary":633,"conditions":634,"keywords":637,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":640,"lastUpdatePostDateStruct":641,"startDateStruct":643,"completionDateStruct":645,"leadSponsor":646,"locationsCount":77},"100358895","pharmacogenetics-of-antidepressant-induced-disinhibition-100358895","NCT03953014","Pharmacogenetics of Antidepressant-Induced Disinhibition","Pharmacogenetics of Antidepressant-Induced Disinhibition in Children Study","PGx-AID","Inclusion Criteria:\n\n1. Aged 6 - 24 years\n2. Medical records available\n3. Diagnosis of MDD, anxiety disorder, or OCD\n4. Current or past history of SSRI therapy\n\nExclusion Criteria:\n\n1. Inability of parent\u002Flegal guardian to give informed consent\n2. Inability of the child to give informed assent\n3. Unwillingness of child to provide saliva sample for genetic analysis\n4. Current, past or suspected diagnosis of attention deficit hyperactivity disorder, oppositional defiant disorder, conduct disorder, bipolar disorder, psychotic disorder, or pervasive developmental disorder.","6 Years",{"count":632,"type":22},120,"The purpose of this study is to identify pharmacogenetic profiles associated with selective serotonin reuptake inhibitors (SSRI)-induced behavioral disinhibition in children with Major depressive disorder (MDD), anxiety disorders and\u002For obsessive-compulsive disorder (OCD) that could be used clinically to reduce the incidence of this adverse event and improve health outcomes.",[635,28,29,636],"Obsessive-Compulsive Disorder","Antidepressant Drug Adverse Reaction",[638,95,67,416,66,639],"SSRI","Antidepressants","2026-05-11",{"date":642,"type":40},"2026-05-14",{"date":644,"type":40},"2019-01-02",{"date":594,"type":22},{"name":647,"class":150},"University of Calgary",{"id":649,"slug":650,"hasResults":12,"nctId":651,"briefTitle":652,"officialTitle":653,"acronym":4,"eligibilityCriteria":654,"healthyVolunteers":12,"sex":17,"minAge":114,"maxAge":655,"enrollmentInfo":656,"targetDuration":4,"studyType":23,"phases":658,"briefSummary":659,"conditions":660,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":661,"lastUpdatePostDateStruct":662,"startDateStruct":663,"completionDateStruct":665,"leadSponsor":667,"locationsCount":77},"100587519","a-preventive-behavioral-intervention-for-young-adults-with-psychotic-experiences-100587519","NCT06929442","A Preventive Behavioral Intervention for Young Adults With Psychotic Experiences","A Randomized Controlled Trial of a Preventive Behavioral Intervention for Young Adults With Psychotic Experiences","Inclusion criteria:\n\n1. 18-30 years old\n2. Enrolled as a first or second year student (i.e., freshman or sophomore) in an undergraduate program at the college or university where the intervention takes place\n3. Students who endorse some psychotic experiences (Peter's et al. Delusion Inventory (PDI) score \\> 3)\n\nExclusion criteria:\n\n1. Inability to provide informed consent\n2. Not proficient in English\n3. Current self-reported Diagnostic Statistical Manual 5 (DSM-5) diagnosis with active symptoms (such as active psychotic symptoms, current suicidality, serious active alcohol or substance use, marked deterioration in functioning over the prior month) determined by clinical interview with participant, or self-report of a psychiatric diagnosis that necessitates close monitoring or individual therapy and\u002For inpatient or partial hospitalization\n4. Current enrollment in psychological or behavioral health treatment.\n5. Current use of psychotropic medications (other than stimulants) prescribed by a physician.\n6. A diagnosis of a serious, chronic mental illness as determined by the Mini-International Neuropsychiatric Interview (MINI)","30 Years",{"count":657,"type":22},192,[119],"This is a randomized controlled trial testing the efficacy of Resilience Training in college students with elevated transdiagnostic risk for developing a serious mental illness.",[505,92,28],"2026-05-07",{"date":640,"type":40},{"date":664,"type":40},"2025-02-10",{"date":666,"type":22},"2029-06",{"name":430,"class":150},{"id":669,"slug":670,"hasResults":12,"nctId":671,"briefTitle":672,"officialTitle":673,"acronym":4,"eligibilityCriteria":674,"healthyVolunteers":16,"sex":17,"minAge":410,"maxAge":675,"enrollmentInfo":676,"targetDuration":4,"studyType":23,"phases":678,"briefSummary":679,"conditions":680,"keywords":681,"overallStatus":170,"whyStopped":4,"lastUpdateSubmitDate":684,"lastUpdatePostDateStruct":685,"startDateStruct":686,"completionDateStruct":688,"leadSponsor":690,"locationsCount":48},"100608551","quantifying-multi-step-avoidance-in-anxiety-100608551","NCT07203027","Quantifying Multi-step Avoidance in Anxiety","Quantifying Neural Signatures of Multi-step Avoidance Behavior in Anxiety","Inclusion Criteria:\n\n* Ability to comprehend written and spoken English\n* Ability to provide informed consent\n* Estimated intelligence quotient (IQ) \\>70.\n* Clinically significant anxiety symptoms (scoring above clinical cutoff on at least one Inventory of Depression and Anxiety Symptoms (IDAS) anxiety-related subscale and\u002For OASIS total)\n* Significant anxiety-related avoidance (scoring 2 or above on a 0-4 scale, indicating at least \"occasional\" avoidance) on the avoidance-related question on the Overall Anxiety Severity and Impairment Scale (OASIS)\n* Functional impairment, defined as at least moderate impairment in one WHO Disability Assessment Schedule (WHODAS 2.0) domain related to anxiety.\n\nExclusion Criteria:\n\n* Individuals younger than 22 or older than 55,\n* Individuals with an IQ \\\u003C 70,\n* A lifetime history of neurological disorder or brain damage,\n* Contraindications for undergoing MRI scanning,\n* A lifetime history or diagnosis of psychosis or bipolar disorder,\n* Current substance use intoxication or withdrawal,\n* Severe risk of suicide, or\n* Recent (\\\u003C3 months) changes in psychotropic medicine or psychotherapy treatment,\n* Ineligible at the PI's discretion, are excluded.","55 Years",{"count":677,"type":22},163,[119],"This study aims to learn more about avoidance behavior in people with anxiety, using mathematical models of decision-making processes and decoded neural signals of threat imminence.\n\nResearchers are investigating anxiety-related behavior and brain function in people with and without anxiety. Investigators are also looking at how behavior and brain function during tasks in the lab relate to avoidance in their daily lives. The investigators will also test whether changing how people avoid things in a behavioral task affects how people avoid things in their everyday life.",[66,28],[682,683],"Avoidance behavior","Fear learning","2026-05-05",{"date":661,"type":40},{"date":687,"type":22},"2027-01",{"date":689,"type":22},"2030-06",{"name":691,"class":150},"Emory University",{"id":693,"slug":694,"hasResults":12,"nctId":695,"briefTitle":696,"officialTitle":697,"acronym":4,"eligibilityCriteria":698,"healthyVolunteers":12,"sex":17,"minAge":114,"maxAge":19,"enrollmentInfo":699,"targetDuration":4,"studyType":23,"phases":701,"briefSummary":702,"conditions":703,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":705,"lastUpdatePostDateStruct":706,"startDateStruct":707,"completionDateStruct":709,"leadSponsor":711,"locationsCount":77},"100595112","mindful-self-compassion-for-anxiety-and-depression-impact-of-delivery-method-100595112","NCT07028216","Mindful Self-compassion for Anxiety and Depression: Impact of Delivery Method","Mindful Self-Compassion for Anxiety and Depression: A Randomized Comparison of In-Person Versus Videoconference Delivery","Inclusion Criteria:\n\n* Must have a primary anxiety disorder (social anxiety disorder, generalized anxiety disorder, panic disorder, or agoraphobia) or major depressive disorder, current\n* Must score low on self-compassion, as measured by the self-compassion scale\n* Must understand study procedure and willing to participate in all testing visits, and treatment as assigned\n* Must be able to give informed consent to the study procedures\n\nExclusion Criteria:\n\n* Comorbid psychiatric disorder other than anxiety or depression, such as psychotic disorder, obsessive compulsive disorder, eating disorders (i.e., anorexia and bulimia), bipolar disorder; developmental or organic mental disorders; and current (past 6 months) substance use disorders and current post-traumatic stress disorder as assessed by clinician at screening visit\n* A serious medical condition that may result in surgery or hospitalization.\n* A history of head trauma causing prolonged loss of consciousness, or ongoing cognitive impairment\n* Inability to understand study procedures or informed consent process, or significant personality dysfunction likely to interfere with study participation (assessed during the clinical interview).\n* Subjects who will be non-compliant with the study procedures. This may include planned travel out of town.\n* Subjects taking some psychiatric medication such as barbiturates or antipsychotics. Sleep medications and some anti-depressants will be allowed, if the subject has been taken at stable dose 8 weeks prior to baseline and the patient plans to continue at the same dose through the trial.\n* Concurrent psychotherapy initiated within 1 month of screen interview, or ongoing psychotherapy of any duration directed specifically toward the treatment of anxiety (such as Cognitive Behavioral Therapy).\n* Individuals who have completed a course of MSC or an equivalent meditation training in the last year.\n* Individuals reporting significant active suicidal ideation or suicidal behaviors within the past year.\n* Individuals with a medical condition (i.e., epilepsy) that may be exacerbated by study treatment, as determined by a study physician or nurse practitioner based on history, physical, and\u002For labs.\n* Adults unable to consent\n* Pregnant women\n* Prisoners",{"count":700,"type":22},80,[119],"The study will compare the delivery of an 8-week Mindful Self-Compassion training, in-person against video-conference, on anxiety and depression symptom severity in patients with diagnosed anxiety disorders (generalized anxiety disorder, social anxiety disorder, and panic disorder) or major depressive disorder or dysthymia.",[28,251,252,193,254,29,704],"Persistent Depressive Disorder (Dysthymia)","2026-05-03",{"date":684,"type":40},{"date":708,"type":40},"2025-06-01",{"date":710,"type":22},"2027-08-31",{"name":263,"class":150}]